Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA

• Company gains further clarity on the additional information required to advance its PMA review • FDA did not request an additional clinical trial following its 100-day review of the PMA application • Company does not currently expect a material change to its overall regulatory timeline TORONTO, Sept. 11, 2026 (GLOBE NEWSWIRE) — Spectral Medical […]